BIAF Latest Headlines

bioAffinity Technologies Highlights Sputum-Based Test Research for Asthma and COPD Biomarkers Ahead of CHEST 2026

Market Chameleon (Tue, 13-Oct 11:23 AM)

BIAF Closes $4 Million Financing at $6.122, Highlighting the Dilution Math Behind CyPath® Lung Funding

Market Chameleon (Mon, 12-Oct 11:18 AM)

BIAF slides as bioAffinity targets about $4 million at-the-market registered direct financing

Market Chameleon (Fri, 9-Oct 11:02 AM)

BIAF jumps after Japanese patent allowance for CyPath Lung’s AI-driven lung cancer prediction method

Market Chameleon (Thu, 8-Oct 10:24 AM)

BIAF Wins Japanese Patent Allowance for CyPath Lung’s Flow Cytometry + AI Method

Market Chameleon (Thu, 8-Oct 8:44 AM)

bioAffinity Technologies points to 1,620 CyPath Lung tests delivered through Q3 2026 as physician adoption expands

Market Chameleon (Tue, 6-Oct 9:28 AM)

BIAF Highlights 2,000-Patient VA/Military FlowPath Lung Study as CyPath Lung Heads to NAVREF 2026

Market Chameleon (Tue, 22-Sep 11:41 AM)

bioAffinity to spotlight CyPath Lung’s veteran-focused study and 92% sensitivity data at NAVREF 2026

Market Chameleon (Tue, 22-Sep 8:33 AM)

BIAF jumps as CyPath Lung expands patent protection into Hong Kong, reinforcing its lung-nodule diagnostic moat

Market Chameleon (Fri, 18-Sep 9:53 AM)

BIAF Highlights Hong Kong Patent Grant as CyPath Lung Targets a Region with 1.6 Million New Cases Annually

Market Chameleon (Thu, 17-Sep 8:39 AM)